Y Combinator Startups in Boston 2024

Ginkgo Bioworks is the organism company. We design custom organisms for customers across multiple markets. We build our foundries to scale the process of organism engineering using software and hardware automation. Organism engineers at Ginkgo learn from nature to develop new organisms that replace technology with biology.

Sendwave's mission is to make sending money as easy and affordable as sending a text. Our app sends transfers securely from North America and Europe to Africa, Asia, and the Americas at great rates.

NewsBlur is a personal news reader that brings people together to talk about the world. A new sound of an old instrument.

Panorama is a fast-growing national technology company focused on improving education. More than 2,000 school systems serving 15 million students across 50 states have adopted our platform to understand students’ academic and social-emotional strengths and to identify those in need of additional support. School systems turn to Panorama's suite of tools to ensure that every child gets the support they need, including school climate and social-emotional learning surveys, tiered intervention planning, and professional development.

TetraScience provides the world’s first and only R&D Data Cloud, with a mission to transform life sciences R&D, accelerate discovery, and improve human life. Scientists at global pharma and biotech organizations rely on our innovative Tetra Data Platform for easy access to centralized, harmonized, and actionable scientific data to accelerate their digital lab transformation. With best-in-class SaaS performance, a team of industry innovators, and excellent product/market fit, Tetra is positioned to become an iconic life sciences software company.

Solar power is the #1 source of new energy in the world. Raptor Maps is a fast-growing, MIT-born startup that builds software to manage the solar lifecycle. We are deployed across 45 countries and 200+ million solar panels. Our software enables the solar industry to scale. We're headquartered at Greentown Labs, the largest cleantech incubator in the US and also support fully remote employees.

Kaymbu is the leading visual messaging and authentic assessment platform for early education. From photo sharing to student portfolios, school newsletters and dynamic photo books, Kaymbu connects early childhood educators with young, digital-native parents. Kaymbu captures the essence of student development and strengthens relationships between home and school.

Sandbox Banking provides a low-code platform to quickly build and run banking integrations. Our software is literally a web application named Glyue, and it's typically used by banks, credit unions, and fintechs to connect banking systems. Glyue integrations are often web service APIs, batch ETL jobs, file/document transfer jobs, or event-driven pub/sub services (e.g. web hooks, Kafka streaming data pipelines).

Technology finds information and delivers physical products to us almost instantly. mRNA does the same for biology. At HelixNano, we see a world where treatments are cheap, progress is decentralized, and you can modify biology at the push of a button. By focusing on mRNA improvements from first principles, we’re getting there faster than we thought. Experiments that used to take months or years can be done in weeks and cost thousands instead of millions. The rate limiting step for our progress is now scientific curiosity. Rigid hierarchies and top-down decisions will miss the magic. Some of our most powerful technologies started out as side projects of junior team members. At HelixNano, every individual scientist can have a massive impact on the company's direction. And the more diverse our team, the faster we’ll find the really cool ideas. We've started rolling out some of our new tech — moving a COVID-19 vaccine candidate for the immunocompromised towards the clinic, and testing an intervention with massive environmental impact. But we’re scientists at heart, and team focus is solidly on the horizon.

Biobot Analytics develops cutting-edge technology to transform sewers into public health observatories. Wastewater contains valuable information about the health of communities. We collect it. We analyze it. We tell you how to leverage it to make your city better. Our first product is to measure opioids and other drug metabolites in sewage to estimate consumption in cities. With this data, those working on harm reduction can assess the scope of the epidemic, allocate resources, and gauge the effectiveness of programming over time.

Reverie Labs is engineering next-generation, brain-penetrant cancer therapies.

We deploy location beacons to track the movements of patients and doctors, measure the inefficiencies in the doctors’ workflows, and then give the hospitals targeted recommendations on how to improve.

Impactive, backed by YCombinator and Higher Ground Labs, was founded in 2017 as a get-out-the-vote tool for Democrats. The Impactive product has since expanded to become a full-service platform allowing any campaign or cause to engage in distributed organizing. In the 2018 midterms, volunteers contacted over 1 million voters using Impactive. In 2020, we scaled significantly to meet the demand of this unprecedented election cycle. We’ve worked with over 500 clients nationwide, and volunteers have sent over 100 million text messages on behalf of Planned Parenthood, the DCCC, SEIU, Community Change, When We All Vote, Greenpeace, and campaigns up and down the ballot. Our work has been featured in The New York Times, Washington Post, TechCrunch, Fast Company, and many more. In 2021, Impactive will expand its platform further into nonprofit, advocacy, and additional markets. This will be an exciting time to play a critical role in helping shape the direction for what’s coming next. We will continue to prioritize our progressive values while building a feature-rich platform that will broaden our reach across the impact space.

Alpha Vantage provides enterprise-grade financial market data through a set of powerful and developer-friendly data APIs and spreadsheets. Whether you need traditional asset classes (e.g., stocks, ETFs, commodities), economic metrics, foreign exchange rates, cryptocurrencies, fundamental data or even technical indicators, Alpha Vantage is your one-stop shop for global market data delivered through REST APIs.

Ascen is a back office platform and employer of record for staffing firms.

Community Phone Company YC W19 built a simple cloud phone system that runs inside of landlines Our solution lets a business or family get all modern voice features (re-route if busy, greeting menu and IVR, programmable caller ID, cloud voicemail, etc) on their existing desk phone and existing cell phones. All employees onboard instantly, no wifi required, no app to download.

Volta Labs is a genomics applications company that has developed a cutting-edge digital fluidics platform to maximize performance and scalability of sample preparation in genomics while providing unparalleled consistency. Volta is transforming the way biological research and analyses are performed, allowing scientists to focus on what they do best -- pushing the boundaries of biology. As a collective of scientists and builders working at the intersection of engineering and biology, we imagine a world where extracting vital information from biological samples is as simple as pressing a button. That's our vision, and we're turning it into reality. Our HQ is in Boston’s Seaport, where we develop and manufacture our technology. We believe in cross-functional collaboration and continuous learning – whether your interest is in biology, MechEng, CompEng, or simply joining a fast-growing startup striving to make the world a better place, we'd love to welcome you to our team. Check out some of our blog posts to learn more about work life at Volta.

At XGenomes, we are building a technology comprising novel biochemistry, hardware and algorithms for sequencing DNA. Our product will be streamlined: there is zero library preparation; we sequence directly on unadulterated single molecules of DNA; DNA extraction will be integrated with sequencing; there is no bioinformatics bottleneck. The sequence we produce will be of unprecedented accuracy due to several layers of in-built redundancy including the sequencing both strands of the double-helix concurrently. The sequence we produce will be complete, encompassing: structural as well as single nucleotide variants; long-range haplotype phase; the repetitive "dark matter" of the genome. The cost of goods (consumables) of sequencing will be <$10, which will allow us to price our product at a level that will help grow the market while still achieving >90% margin. We will start by offering access as a service to high value customers, which be followed by a razor and blade model of selling instruments and consumables.

We are a biotechnology company integrating AI, computation and biological automation to accelerate the design of small molecule and protein therapeutics. Our mission is to decrease the timeline and cost of drug development, while improving the success rate of bring innovative medicines to patients in need. We have two drug discovery engines - ELVIS™ and ROSALYND™ - that enable the design of both small molecule and protein therapeutics, an unmatched capability in the AI drug discovery space. Our therapeutic area-agnostic, end-to-end technology powers the full length of early drug discovery - from novel hit discovery to hit to lead, and lead optimization. We are currently applying our technology to drug discovery programs in several areas including, but not limited to, neuroscience, infectious disease, immunology and oncology.

DNA has emerged as a compelling data storage medium due to its density, longevity, and eternal relevance compared to current memory technologies. However, the high price of synthesizing DNA remains a major bottleneck for adoption of this promising storage solution. We are pioneering new approaches to synthesizing DNA for data storage with enzymes and custom digital codecs. We are building an interdisciplinary team to build the world's most scalable information infrastructure in DNA. We seek technical experts in enzyme engineering, chemistry, hardware engineering, and information theory. We also seek business development to identify emerging markets for early use cases of our technology.

Software that simplifies electric grid forecasting and operations. Clients--hard assets like wind, solar and energy storage--get timely, unbiased information to improve revenues, reduce risk, and maximize the profitability of every megawatt. Gaiascope also manages a quant fund trading electricity; with this fund, the company builds additional credibility with clients and accelerates the continuous improvement of its software.

Vendr helps software buyers pay less for software and helps software sellers acquire customers at a lower CAC -- a no brainer for both buyers and sellers. $4 billion+ of software transacted on Vendr, across 2,500+ software sellers.

Stealth-mode, rapidly scaling, venture-backed startup at the vanguard of automated robotic surgery revolution -- just closed our Series A round. We are improving access to dental care in underserved populations by combining novel imaging technology with AI and surgical robotics to automate surgery in the $452B dental industry. We are bringing a new imaging modality to dentistry which can see inside teeth and below the gingiva all without the need for x-rays. AI is used to diagnose decay and plan treatment. Automated robotics reduces the time for surgery down to one minute, reducing patient discomfort and saving time and reducing cost for the dentist. YC 2020, Winner of the Forsyth DenTech 2021 CareCaptial award

Metaplane ensures everyone trusts the data that powers your business. Data teams at Bose, Ramp, and Klaviyo use our data observability platform to prevent and detect data issues — before the CEO pings them about weird revenue numbers. We do this with ML-based anomaly detection, end-to-end column-level lineage, and tools to help prevent incidents before they occur. You can monitor your entire data stack within 30 minutes. The company is backed by Khosla Ventures, Y Combinator, and the founders of Okta, HubSpot, and Vercel.

PostEra is building a modern 21st century biopharma. We're using our advances in machine learning to accelerate Medicinal Chemistry and bring more cures to patients. PostEra advances small molecule programs through partnerships with biopharma while also advancing its own internal pipeline. We've raised $26M from top investors and closed $1Bn in AI partnerships, signing multi-year agreements with Amgen, Pfizer and the NIH. PostEra also launched and led the world's largest open-science drug discovery effort; COVID Moonshot.

We are a nonprofit stool bank, expanding safe access to fecal transplants and catalyzing research on the human microbiome.

Kernal Bio creates mRNA 2.0 therapies that instruct specific cells on how to make their own medicine. Kernal Bio encrypts mRNA’s “message” in a language that only cancer cells understand. These tumor-specific mRNA therapeutics allow precise targeting of cancer cells, without harming normal cells or tissues. They have recently been validated in preclinical tumor models, showing high efficacy and safety as well as durable adaptive immunity. With roots at MIT, Harvard and Biopharma, Kernal’s management team has deep expertise in mRNA therapeutics space. CEO Yusuf Erkul, M.D., M.B.A. is a successful drug hunter whose research at Merck enabled an FDA-approved drug for ovarian cancer. President, Burak Yilmaz, M.S., previously founded Sentegen, a thriving synthetic biology company which commercializes synthetic DNA, RNA, and diagnostic kits for genetic and infectious diseases. VP of BD, Matt Strout, M.D. Ph.D., M.B.A, is a business development executive who led more than $4.5B worth of BD deals at Alexion and AstraZeneca. VP of R&D Manfred is a leader in immuno-oncology, who was most recently Scientific Senior Director at Bristol-Myers Squibb (BMS).

Nextera Robotics is an AI-native Robotics and Industrial Automation company founded at MIT.

Our mission is to enable pharmaceutical and biotech companies to bring more antibody therapies to patients. Using AI and massively parallel experimentation, we design antibodies that precisely bind the disease target at the right location, while minimizing manufacturability and toxicity risks. We are a well-funded, revenue-generating, bilingual company of wet- and dry-lab scientists, and are founded by AI and protein design experts from Harvard University.

REGENT is building a new mode of transportation that will redefine regional mobility by mid-decade. Their first product, the seaglider, is an all-electric, hydrofoiling boat-plane that operates within a wingspan of the water's surface. By flying low on a cushion of air, seagliders unlock the ability to fly twice as far as an electric aircraft, while being regulated by maritime authorities enabling market entry for a fraction of the cost. REGENT has de-risked seaglider technology with a ¼-scale, 400 lb, flying demonstration vehicle and a full-scale wing test section. By 2024, REGENT will fly humans on the first full-scale prototype seaglider. By mid-decade, REGENT’s customers - airlines and ferry companies – will begin commercial seaglider service on the 12-seat initial product. In just two years, REGENT has accumulated $8B in provisional orders (including firm deposits) proving the potential of the $25B+ initial market. REGENT, a team of 40, is led by MIT-trained, ex-Boeing engineers Billy Thalheimer and Mike Klinker. REGENT has raised $50M to date from the likes of Thiel Capital, Founders Fund, Mark Cuban, Y Combinator, and includes strategic investment from Japan Airlines, Hawaiian Airlines and Mesa Airlines.

We are building a platform of bacterial molecules to awaken our body’s innate ability to control inflammation and heal. Our first indication is Crohn’s Disease, which affects over 500,000 Americans at an annual cost of $10B. After Crohn's disease, we are going for type 1 Diabetes and Multiple Sclerosis.

Parallel Bio created a human 'immune system in a dish' to discover drugs and immunotherapies more likely to work in patients. Our platform has all of the same elements as a human immune system, meaning you can test drugs and vaccines as if you were testing them in actual patients from the start. The biggest reason why 95% of new drugs fail is that they were tested in mice - but with our human platform, pharma companies will know which drugs will successfully treat patients, speeding up the process and reducing the cost. To date our platform has successfully been used to test 12 drugs, and vaccines against 8 different diseases. The company is founded by Robert DiFazio, a former Stanford R&D director with a PhD in immunology, and Juliana Hilliard, a former System1 Biosciences R&D lead with an MSc in bioengineering, both of whom have led drug discovery programs for years.

At Pirouette, we have developed a low-profile, disk-shaped, rugged injection device with a patient-centric focus on affordability, portability, and usability. The patented device, based on extensive patient input, is designed to make administering an injection as easy as pushing a button. This allows individuals with limited or no training to easily and intuitively perform an injection on themselves or others.

KaiPod Learning is a national network of microschools bringing school choice to every community in America. We work with education entrepreneurs to start high-quality community-based microschools to better serve students and their families. As more families stand up for choice in education and as more educators look for alternative career pathways, KaiPod Learning is helping bring microschools into the mainstream.

Kiwi Biosciences can help 18M Americans suffering from Irritable Bowel Syndrome (IBS) enjoy a normal meal without running to the bathroom two hours later. We develop novel, patent-pending enzymes that break down common digestive triggers in food.

Non-invasive brain stimulation is a widely-utilized, FDA cleared treatment used for patients diagnosed with depression, but is limited to a hospital setting due to the cost of the device, and complexity of treatment application. Our proprietary brain stimulation device allows patients to be treated directly from their home, with the same efficacy, and at a lower cost of treatment. Currently in FDA pivotal phase for Major Depressive Disorder, and Pilot phase for Alzheimer's and Parkinson diseases.

Brown Foods is a Stanford, Rice University and IIT Delhi alumni venture building the next-generation of food products. They are creating UnReal Milk- lab based, clean milk - extremely sustainable 'real milk' but made without any cows. Unlike any other option in the USD 22 billion dairy alternatives market today, it will be exactly similar to cow’s milk in terms of nutritional profile, taste, texture and could also be processed into butter, cheese and ice creams. They envision to disrupt the USD 700 billion conventional dairy market by giving the world its 1st 'cow free' real milk option, reducing the carbon footprint of milk by over 90% while being completely cruelty-free.

We are building high-precision implantable neuromodulation devices that can sense and stimulate neural activity in the brain with the goal of transforming the efficacy and adoption of deep brain stimulation (DBS), an existing FDA-approved therapy used to treat Parkinson’s, essential tremor and epilepsy.

Argument combines zero-knowledge cryptography, formal verification and distributed consensus technologies to build systems for unbreakable, scalable, private, decentralized software.

Fortuna Genomics employs methods from revolutionary genomics studies to non-invasively assess embryo traits, enabling parents to optimize their children's innate qualities without the need for gene editing. Through comprehensive genetic screening and forecasting, it empowers families to make informed decisions, optimizing their child’s well-being and capabilities from conception. With the convergence of advancements in genomic technologies, association studies, and sequencing efficiency, we are at a unique inflection point where such services can become widely accessible and impactful. Accurately predicting complex traits from genetic markers involves sophisticated models that must account for the interplay between countless biological and statistical factors. Our team is well-equipped to tackle this problem and make every parent's dream a reality by allowing them to give their children the best possible start in life.

Navigating chronic illness is an isolating and lonely process which ultimately reduces medical adherence and adversely impacts outcomes. There are over 100 deadly chronic conditions as 1 out of 2 Americans is currently living with at least 1 chronic condition. The US healthcare system has over $1 trillion dollars in direct costs. Medical adherence rates for therapeutic programs and medicine are only 50% because patients feel lonely, isolated, and unsupported in their chronic illness journey. Reviving Mind is an in-network telehealth provider that improves clinical outcomes and program adherence for the senior medicare and medicare-advantage population that is plagued with loneliness and chronic illness. This is done through a novel and proprietary clinical program and technology platform that integrates virtual, private, curated, and professionally led groups that scale up to 8-patients with individualized and goal oriented lifestyle medicine coaching that is automated but managed by a licensed provider. Scaling rapidly across the United States.

NuMind is a tool for data scientists, data analysts, but also software engineers to create custom NLP models. For example, a recruiting company uses NuMind to find which job offers best match a given resume. Etienne (CEO) was head of Machine Learning at Wolfram Research, and Samuel (CTO) co-founded Make.org (8M users). NuMind originated from our own frustration when developing NLP models. Leveraging large language models similar to GPT-3, NuMind allows to complete NLP projects at least 10x faster than before. We launched a private beta August 2 and had 9 paying customers one month later.

FlyCode Dunning & Payment Management AI that helps subscription merchants maximize revenue. We reduce passive churn by managing payment failures intelligently. We’re Jake, Etai, and TD and we’re building FlyCode. TL;DR: If you sell SaaS or B2C subscriptions, we’re here to help you recover lost revenue due to failed payments and involuntary churn. ‘Involuntary’ or ‘Passive’ churn is a hidden Revenue Killer 💳 for Subscription Businesses ❌ THE PROBLEM: Recovering Failed Payments is Complex Involuntary churn refers to the loss of subscribers due to payment failures, not due to them actively canceling. While it is both possible and a worthwhile strategy to attempt to win back a customer during the cancellation process — involuntary churn is not intentional and in most cases, your customers aren’t even aware that their payment failed. 💰 Bottom line? Effective payment optimization does reduce involuntary churn and will increase ARR by as much as 5-10% FLYCODE SOLUTION 💡 FlyCode leverages ML and AI to provide Payment Optimization and smart payment retries to maximize subscription revenue and reduce churn. We apply a unique model tailored to each Merchant and their customers to ensure optimal results. ⚡️Automatically recover failed subscription payments and reduce passive churn ⚡️Use ML & AI based payment optimization to find the best time to charge your customers ⚡️ Improve customer experience by coordinating payment retries with customer emails/SMS 🛠️ We support OOTB + Custom Integrations for Merchants and White-Label for Platforms

Your immune system is your body’s best weapon and defense against cancer. It is only when it is overcome that cancer develops into full blown disease. Dendritic cells sit at the helm of the immune system, directing and dictating immune responses. Data has shown dendritic cells are often dysfunctional in cancer patients, and that this dysfunction is a bottleneck for other therapies. Guardian Bio’s approach is focused on creating a dendritic cell-based product which drives anti-tumor activity through activating the killers of the immune system AND training them against multiple cancer targets. We take stem cells from cancer patients, turn them into specific therapeutic dendritic cells specially trained against that patient’s tumor, and re-introduce them back into the body. Our therapeutic dendritic cells revitalize the killers of the immune system and give them the kickstart they need to fight - and win - against cancer.

Cloudant's distributed database-as-a-service (DBaaS) allows developers of fast-growing web and mobile apps to focus on building and improving their products, instead of worrying about scaling and managing their databases on their own. We manage and distribute your data globally so you can grow more users, build more app features, and sleep more knowing we're keeping the servers up and humming. Cloudant was founded in Cambridge, Massachusetts in 2008 by three MIT physicists who at the time were moving multi-petabyte data sets around from the Large Hadron Collider. Frustrated by the available tools for managing and analyzing Big Data in their research, the founders built a distributed, fault-tolerant, globally scalable data layer on top of Apache CouchDB. The service has grown since then. The team now manages and serves mobile and web app data on behalf of thousands of developers and hundreds of customers to their users around the world. In 2014, the company was acquired by a global enterprise software & hardware vendor.

Embedly provides a platform and suite of tools to make embedding and previewing links simple. Embedly helps publishers and consumers manage embed codes from more than 100 Websites and APIs, including YouTube, Flickr, Ustream, Picassa, Hulu, Twitpic, Quantcast, and CrunchBase. It automatically convert links from these sources into embedded media on the fly.

Kiko is a web calendar for anyone who wants to keep and share a calendar online. Kiko excels at three main things: * Universal access: Kiko integrates with your mobile phone and AIM and lets you access your calendar from any computer. * Share your calendar: Invite anyone to events (not just other Kiko users!) Let others view your calendar with just a click. * As easy as paper - or maybe easier: Write "Pay gas bill every month" onto your calendar and watch Kiko do the Right Thing!

At Moltin, we believe that brand experiences should never be obscured by technology and that commerce development should be simple, lightweight and fun. Moltin is an API-first digital commerce solution that enables retailers to build distinctive shopping experiences and embed them into any consumer touchpoint. It combines an extremely flexible set of APIs, developer toolkits, pre-built applications and cloud infrastructure to make commerce development simple, lightweight and fast. Moltin APIs are the simplest, most powerful in the industry. Retailers can test new channels quickly, scale into new markets, and keep pace with ever-evolving consumer trends. With Moltin, commerce flows seamlessly across any channel, device and experience. Moltin has a rapidly growing community of more than 17,000 developers around the world, pushing the boundaries of traditional commerce.

Pretty Instant was a Y Combinator-backed marketplace for professional photography and videography in the U.S., active from 2012 to 2020. Acquired by Snappr in 2021, the company served over 2,000 brands and non-profits, handling logistics, staffing, editing, and delivery. It became a go-to solution for companies seeking streamlined visual content creation. Services included photography and videography for Events, Portraits, Real Estate, Product, Food, and more. Photographers were thoroughly vetted 1099 contractors, ensuring quality and reliability. Pretty Instant aimed to simplify hiring processes for businesses needing professional visual content.

Hunter2 teaches modern appsec to engineering teams through interactive labs. Developers get hands-on practice exploiting and patching real web apps written in their tech stack.

We’re a group of Harvard and Yale-trained physicians, engineers, designers, and social entrepreneurs who came together to transform care delivery. Medumo’s CareTours™ enable healthcare organizations to effectively provide turn-by-turn guidance to patients without disrupting workflow by utilizing automated, precisely-timed messages sent via text and email. - Dramatically improve procedural completion rate - Increase referral conversion - Reduce staff burden - Recover revenue loss Want to get started in automating patient navigation for your Hospital, ASC, or Practice? We serve all specialties. Reach out to our leadership team for a brief chat or full presentation. Bob Smith - Director Strategic Partnerships Bob@medumo.com Cell # is 502-744-2911 EST

The biggest social network in the world for TikTok celebs. One of the first 5 companies in the US to get the TikTok API. Launched over 400 companies on TikTok in under a year. Work with Ridge, Hopper, and more. Acquired in 2021.

We use machine learning to accurately forecast electricity prices. Our live customers, including Enel, use our software to improve revenue by millions of dollars per year.